Discover and read the best of Twitter Threads about #mAbs
Most recents (4)
Do mRNA vaccines induce antibody-dependent enhancement (ADE)-causing antibodies also?
We know mRNA vaccines generate robust neutralizing Abs, but vaccines targeting the S-protein, the possible induction of ADE of infection is a concern. 1/
We know mRNA vaccines generate robust neutralizing Abs, but vaccines targeting the S-protein, the possible induction of ADE of infection is a concern. 1/
Recent reports have demonstrated that neutralizing #mAbs against S-protein can exhibit ADE activity in a limited window of Ab concentrations. These reports have demonstrated that some anti-S protein mAbs have the potential to induce ADE of infection. 2/
Several mechanisms leading to #ADE, which can be FcR-dependent but ACE2-independent, FcR-independent but ACE2-dependent, S-protein conformational change-dependent, or both FcR- and ACE2-dependent ADE. 3/ 
Latest @WHO #TechnicalBrief on #Omicron
Overall risk remains very high & threat depends on
1⃣Transmissibility of #variant
2⃣How protective vaccines & prior infection are
3⃣Virulence of variant
4⃣Understanding of dynamics & uptake PHSM
Full 🧵👇 (1/)
who.int/publications/m…
Overall risk remains very high & threat depends on
1⃣Transmissibility of #variant
2⃣How protective vaccines & prior infection are
3⃣Virulence of variant
4⃣Understanding of dynamics & uptake PHSM
Full 🧵👇 (1/)
who.int/publications/m…
Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2
ORF3a Transmembrane Protein
#Orf3a #SARSCoV2
#mAbs
1/n
mdpi.com/1999-4915/13/1…
ORF3a Transmembrane Protein
#Orf3a #SARSCoV2
#mAbs
1/n
mdpi.com/1999-4915/13/1…
Alors, ces mAbs anti #SARSCoV2 en prévention ou traitement précoce de #COVID19 , on en est où ?! Buzz médiatique ou réelle avancée scientifique ? Jugez ! #croi2021 Thread 1/4
2/4 : BAMLA en prévention chez les résidents d’EHPAD et leurs soignants (BLAZE-2): 1) réduction 80% du risque de formes sympto. (72% si haut risque) 2) charge virale plus faible si infectés 3) pas de décès dans groupe BAMLA (4 si placebo) ==> espoir pour les plus fragiles !
3/4 BAMLA + ETESE (vimab) en prévention des formes graves chez patients s formes légères ou modérés: 1) 70% de diminution du risque d’hospit. 2) réduction significative de la charge virale et durée des symptômes ==> moins de tension en hospitalisation aiguë et réa !
